High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies

This clinical trial is for men and women with resectable or metastatic solid tumor
malignancies. The objective of the study is to investigate whether high dose vitamin C
infusion leads to pathological tumor response in resectable colorectal, pancreatic, and lung
cancer (cohort A) or objective tumor response in KRAS or BRAF mutant solid tumors (cohort B).

Patients enrolled in cohort A will receive high dose Vitamin C infusion for 4 days per week
for 2-4 consecutive weeks prior to surgery. Patients enrolled in cohort B will receive high
dose Vitamin C infusion for 4 days per week up to 6 months. A tumor sample will be resected
after completion of study drug (high dose vitamin C infusion) treatment to examine the
effects of study drug (Cohort A only). In addition, organoids will be grown in vitro and
continue to be treated with vitamin C added in culture medium to examine tumor response. The
resected tumor in this study will

Key eligibility:

- Men and women age 18 and older

- Patients with histologically proven early stage or locally advanced colorectal
adenocarcinoma, lung cancer or pancreatic cancer, who are eligible for resection, and
have not received chemotherapy or radiotherapy (cohort A) Patients with inoperable,
metastatic, KRAS or BRAF mutant colorectal adenocarcinoma, lung cancer and pancreatic
cancer, who have received at least 1 line of treatment for metastatic disease (cohort B)

Inclusion Criteria:

1. Male or female ≥ 18 years of age.

2. Patients with histologically proven early stage or locally advanced colorectal
adenocarcinoma, lung cancer or pancreatic cancer, who are eligible for resection, and
have not received chemotherapy or radiotherapy (cohort A)

3. Patients with inoperable, metastatic, KRAS or BRAF mutant colorectal adenocarcinoma,
lung cancer and pancreatic cancer, who have received at least 1 line of treatment for
metastatic disease (cohort B).

4. ECOG performance status 0-1.

5. Life expectancy of at least 6 months.

6. All women of child-bearing potential and all sexually active male patients must agree
to use effective contraception.

7. Patient with adequate organ and marrow function as follows:

- ANC ≥ 1500 mm3, platelets ≥ 100,000/mm3, hemoglobin ≥ 9 g/dL,

- serum creatinine ≤1.8 mg/dL or creatinine clearance > 50 mL/min (Appendix C:
Estimating Creatinine Clearance);

- bilirubin ≤ 1.5 mg/dL; alanine aminotransferase (ALT), aspartate transaminase
(AST) ≤ 2.5 times the upper limit of normal if no liver involvement or ≤ 5 times
the upper limit of normal with liver involvement.

8. Patients with serum electrolytes (including calcium, magnesium, phosphorous, sodium
and potassium) within normal limits (supplementation to maintain normal electrolytes
is allowed).

10. Patients capable of understanding and complying with the protocol and who have signed
the informed consent document.

Exclusion Criteria:

1. Patients with uncontrolled intercurrent illness including, but not limited to
uncontrolled infection, symptomatic congestive heart failure (NYHA class III and IV),
uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would
limit compliance with study requirements (Appendix B: New York Heart Association
(NYHA) Classifications).

2. Patients with active heart disease including myocardial infarction within previous 3
months, symptomatic coronary artery disease, arrhythmias not controlled by medication,
unstable angina pectoris, or uncontrolled congestive heart failure (NYHA class III and
IV) (Appendix B: New York Heart Association (NYHA) Classifications).

3. Patients who have received systemic chemotherapy or targeted therapy for metastatic
disease within 2 weeks from start of study drug treatment (cohort B).

4. Patients who have received an investigational drug within 21 days of the first dose of
study drug.

5. Patient who have not recovered to grade ≤ 1 from adverse events (AEs) due to
investigational drugs or other medications, which were administered more than 4 weeks
prior to the first dose of study drug.

6. Patients who are pregnant or lactating.

7. Patients who are known to be positive for the human immunodeficiency virus (HIV). The
effect of Vitamin C on HIV medications is unknown. Note: HIV testing is not required
for eligibility, but if performed previously and was positive, the patient is
ineligible for the study.

8. Patients who have the inability or unwillingness to abide by the study protocol or
cooperate fully with the investigator or designee.

9. Patient who are receiving drugs which are known to interact with Vitamin C, potential
risk and eligibility will be evaluated individually by the investigator.

10. Patients who have uncontrolled or severe hyponatremia, hypernatremia, SIADH,
hypokalemia, hyperkalemia, hypomagnesemia, or hypermagnesemia

11. Patients who have uncontrolled or severe coagulopathies or a history of clinically
significant bleeding within the past 6 months, such as hemoptysis, epistaxis,
hematochezia, hematuria, or gastrointestinal bleeding.

12. Patients who have a known predisposition for bleeding such as von Willebrand's disease
or other such condition.

13. Patients who require therapeutic doses of any anticoagulant, including low molecular
weight heparin (LMWH). Concomitant use of warfarin, even at prophylactic doses, is
prohibited.

14. Patients who have uncontrolled seizure disorder, ascites, iron overload, edema, or
dehydration.

15. Patients who have glucose-6-phosphate dehydrogenase (G6PD) deficiency, hereditary
spherocytosis, or other conditions predisposing patient to hemolysis.

16. Patients who have a history of oxalate renal calculi.